Hyperglycemia induced cathepsin L maturation linked to diabetic comorbidities and COVID-19 mortality
eLife · 2024
DOI: 10.7554/elife.92826 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Qiong He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Diabetes Institute, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: COVID-19, Cathepsin L, Hyperglycemia, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Administration of Hospitals.
Abstract (Originalsprache)
Diabetes, a prevalent chronic condition, significantly increases the risk of mortality from COVID-19, yet the underlying mechanisms remain elusive. Emerging evidence implicates Cathepsin L (CTSL) in diabetic complications, including nephropathy and retinopathy. Our previous research identified CTSL as a pivotal protease promoting SARS-CoV-2 infection. Here, we demonstrate elevated blood CTSL levels in individuals with diabetes, facilitating SARS-CoV-2 infection. Chronic hyperglycemia correlates positively with CTSL concentration and activity in diabetic patients, while acute hyperglycemia augments CTSL activity in healthy individuals. In vitro studies reveal high glucose, but not insulin, promotes SARS-CoV-2 infection in wild-type cells, with CTSL knockout cells displaying reduced susceptibility. Utilizing lung tissue samples from diabetic and non-diabetic patients, alongside Lepr db/db mice and Lepr db/+ mice, we illustrate increased CTSL activity in both humans and mice under diabetic conditions. Mechanistically, high glucose levels promote CTSL maturation and translocation from the endoplasmic reticulum (ER) to the lysosome via the ER-Golgi-lysosome axis. Our findings underscore the pivotal role of hyperglycemia-induced CTSL maturation in diabetic comorbidities and complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Beijing Diabetes Institute, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Department of Respiratory and Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Department of Science and Technology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China, Beijing, China.
- Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
ORCID-Profile: Miao-Miao Zhao, Jin-Kui Yang
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals
Zitieren
APA
He, Q., Zhao, M. M., Li, M. J., Li, X. Y., Jin, J. M., Feng, Y. M., Zhang, L., Huang, W. J., Yang, F., & Yang, J. K. (2024). Hyperglycemia induced cathepsin L maturation linked to diabetic comorbidities and COVID-19 mortality. eLife. https://doi.org/10.7554/elife.92826
Vancouver
He Q, Zhao MM, Li MJ, Li XY, Jin JM, Feng YM, et al. Hyperglycemia induced cathepsin L maturation linked to diabetic comorbidities and COVID-19 mortality. eLife. 2024. doi:10.7554/elife.92826
BibTeX
@article{He2024,
author = {He, Qiong and Zhao, Miao-Miao and Li, Ming-Jia and Li, Xiao-Ya and Jin, Jian-Min and Feng, Ying-Mei and Zhang, Li and Huang, Wei Jin and Yang, Fangyuan and Yang, Jin-Kui},
title = {Hyperglycemia induced cathepsin L maturation linked to diabetic comorbidities and COVID-19 mortality},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.92826}
}
EUVIMED